Pharma news
Americas
Five-strong team to open new location in the spring | Office will be led by experienced litigators and patent specialists bringing pharma, biologics, medical devices, femtech, and technology expertise to Chicago. 30 January 2025
Americas
Complex legal battle concerns ‘skinny label’ strategy used by generic drug makers, prompting a $235 million award | Pharma giant looks for enhanced damages due to ‘wilful infringement’, while opponent wants another trial. 29 January 2025
Europe
Munich division asks pharma company for clarity on territorial scope | Sanofi took battle with four generic makers over Jevtana to UPC. 28 January 2025
Americas
Teva insisted panel’s narrow interpretation of ‘claims the drug’ will have a seismic effect on the Orange Book | Stay granted while en banc rehearing is under question | Decision could reshape patent listing standards and impact the availability of generic drugs. 23 January 2025
Americas
Will this year be defined by a concerted shift towards ‘One Health’? Simon Kiddle and Rebecca Tollervey of Mewburn Ellis explore. 23 January 2025
Americas
New president says repeal is first of “many steps the US federal government will take to repair our institutions and our economy” | Defunct order aimed to lower drug costs and place caps on essential medications | Big Pharma argues higher drug prices are necessary to fund R&D for new therapies. 21 January 2025
Pharma
A district court of appeal has paused MSN Pharmaceuticals’ launch | Result comes days after the Federal Circuit restored Novartis’ patent and overturned a decision in favour of MSN | Request is one in a flurry of filings between the pair over the heart-failure drug. 16 January 2025
Americas
PTAB determines all but one of challenged claims unpatentable | Decision is latest instalment in clash over electrocardiogram technology | Apple bid to stop ‘AliveCor’s rampant infringement’ backfires. 9 January 2025
Americas
Key developments for the industry this year include a more pro-patent administration and USPTO changes, say Carla Ji-Eun Kim and Deborah Sterling of Sterne Kessler. 2 January 2025
Americas
Dispute stems from Amneal’s efforts to market generic version of Teva’s inhaler for treating asthma | Precedential decision could restrict how brand-name pharmaceutical companies use the Orange Book to extend market exclusivity. 24 December 2024